2016-08-242016-08-242015-08-11http://hdl.handle.net/10919/72758The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs. This includes but it is not limited to abscisic acid (ABA), ABA analogs, benzimidazophenyls, repurposed drugs or drug combinations, including thiazolidinediones (TZDs); naturally occurring compounds such as conjugated diene fatty acids, conjugated triene fatty acids, isoprenoids, and natural and synthetic agonists of peroxisome proliferator-activated receptors that activate this receptor through an alternative mechanism of action involving LANCL2 or other membrane proteins to treat or prevent the common inflammatory pathogenesis underlying type 2 diabetes, atherosclerosis, cancer, some inflammatory infectious diseases such as influenza and autoimmune diseases including but not limited to inflammatory bowel disease (Crohn's disease and Ulcerative colitis), rheumatoid arthritis, multiple sclerosis and type 1 diabetes and other chronic inflammatory conditions.application/pdfen-USPatenthttp://pimg-fpiw.uspto.gov/fdd/73/015/091/0.pdf131007951/1A61K31/13A61K31/135A61K31/35A61K31/352A61K31/40A61K31/405A61K31/4184A61K31/427A61K31/431A61K31/495A61K31/496A61K31/4985A61K31/517A61K31/545A61K31/55A61K31/56A61K31/57A61K31/65A61K31/655A61K31/704A61K31/7048A61K2300/00G01N33/6872G01N33/573G01N33/6875G01N2333/4703G01N2333/70567G01N2500/02G01N2500/04G01N2500/20G06F19/12G06F19/16G06F19/3456Y10T436/14333Y10T436/14555Y10T436/147779101573